Orphan Drug Action is intended to assist and encourage companies to develop effective and safe therapies for the treatment of rare illnesses and disorders. Orphan Medication designation is certainly awarded to compounds offering potential therapeutic value in the treating rare diseases, defined as those affecting fewer than 200,000 Americans. This designation provides companies with economic and regulatory benefits such as for example eligibility for a particular seven-year period of marketplace exclusivity upon approval for the compound and indication with orphan designation, potential tax credits for research, potential grant funding for development and research, reduced filing fees for advertising applications, and assistance with clinical trial protocol review..Currently just over 55 % of people receive health coverage through their work . This content was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family members Foundation. Kaiser Health Information, an editorially independent news service, is a scheduled program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.. 3D-printed airway splint saves life of infant born with serious tracheobronchomalacia Half of a millennium after Johannes Gutenberg printed the bible, experts printed a 3D splint that saved the life span of an infant born with severe tracheobronchomalacia, a birth defect that causes the airway to collapse.